DiaMedica Therapeutics (DMAC) Total Current Liabilities (2017 - 2026)

DiaMedica Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $5.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 23.22% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 23.22% increase from a year earlier, with the FY2025 full-year figure at $5.1 million, down 4.79% from the prior year.
• Total Current Liabilities advanced to $5.7 million in Q1 2026 per DMAC's latest filing, from $5.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $5.7 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $2.8 million (2023), against an average of $3.3 million.
• Biggest YoY gain for Total Current Liabilities was 98.02% in 2024; the steepest drop was 7.0% in 2024.
• Year by year, Total Current Liabilities stood at $2.2 million in 2022, then increased by 28.51% to $2.8 million in 2023, then jumped by 93.47% to $5.4 million in 2024, then fell by 4.79% to $5.1 million in 2025, then gained by 12.0% to $5.7 million in 2026.
• Per Business Quant, the three latest DMAC Total Current Liabilities figures stand at $5.7 million (Q1 2026), $5.1 million (Q4 2025), and $5.3 million (Q3 2025).